// App-Quantinova.ai

3824 : The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial

Researchers

Presenter

  • Alexander T Cohen

Principal Investigators

  • Rim Halaby

  • Serge Korjian

  • Robert Harrington

  • C. Michael Gibson

  • Yazan Daaboul

  • Donald Szlosek

  • Douglas Arbetter

  • Samuel Z. Goldhaber

  • Russell Hull

  • Adrian Hernandez

  • Alexander Gold

  • Brian Wiens

Medical Centers

  • Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • Department of Haematological Medicine, Guy's and St Thomas Hospitals, King's College, London, United Kingdom

  • University of Calgary, R.A.H Faculty of Medicine,, Alberta, Canada

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • Portola Pharmaceutic

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Pulmonary embolism

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

Drug/Treatment

  • betrixaban

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved